Growth hormone peptides raise aging-claim questions

A wave of clinics and online sellers are pushing growth-hormone peptides like sermorelin and tesamorelin as anti-ageing “elixirs,” promising firmer skin, more muscle and fewer wrinkles. These peptides are fragments of the natural hunger hormone ghrelin that, in theory, prod the pituitary to secrete extra growth hormone. The trend has exploded on social media, where influencers film injections in bathroom mirrors and clinics post before-and-after photos of customers in their 50s and 60s.

The push comes as the global anti-ageing market tops $60 billion and baby boomers chase the fountain of youth. Growth-hormone therapy itself is not new; doctors have used it for decades to treat childhood deficiency and adult wasting in HIV patients. But the older injectable form carried real risks—fluid retention, joint pain, and even diabetes—so researchers developed shorter peptides that allegedly sidestep those problems. The catch is that none of these peptides is FDA-approved for ageing; they are approved only for specific conditions like growth-hormone deficiency or excess abdominal fat in HIV. Off-label use is legal, but the evidence for longevity or cosmetic benefits is thin.

Peer-reviewed studies on sermorelin and tesamorelin do show modest gains. One 2022 trial in older adults found a 10 % increase in lean body mass after six months, while a 2017 study saw a drop in visceral fat—useful for metabolic health. Yet none of these trials tracked whether people lived longer or felt younger. Side effects can still appear: a 2021 review reported joint swelling in about 5 % of users. Prices range from $200 to $500 a month, and compounded versions from unregulated labs may contain contaminants.

Regulators are starting to act. The FDA recently warned clinics about marketing peptides for ageing and issued safety alerts on counterfeit peptides flooding the internet. Meanwhile, scientists are launching larger, longer trials to test whether these drugs can slow age-related decline without the baggage of full growth-hormone therapy. For now, the science does not back the hype, but the market keeps growing.